The global automated nucleic acid extraction market is entering a period of strong expansion as laboratories increasingly adopt automation, molecular diagnostics, genomics, and precision medicine. Valued at approximately US$ 3.6 billion in 2025, the market is projected to reach US$ 11.7 billion by 2036, expanding at a CAGR of 11.4% between 2026 and 2036.

Automated nucleic acid extraction systems are becoming essential in modern laboratories because they enable the efficient isolation and purification of DNA and RNA from biological samples while reducing manual intervention, processing time, and operator-dependent variability.

Growing Adoption of Molecular Diagnostics

The increasing use of molecular diagnostics is one of the major factors driving market growth. Techniques such as PCR, real-time PCR, and next-generation sequencing (NGS) depend on high-quality nucleic acid extraction as a critical pre-analytical step.

As molecular testing expands across infectious disease diagnosis, oncology, genetic testing, and precision medicine, laboratories are processing larger numbers of samples while maintaining stringent standards for accuracy and reproducibility. Automated extraction platforms help address these requirements by delivering standardized workflows, higher throughput, and reduced contamination risks.

The growing shortage of skilled laboratory professionals is also encouraging laboratories to automate repetitive processes. By reducing hands-on time, automated systems allow technicians to focus on more complex laboratory activities while improving overall operational efficiency.

Rising Testing Volumes in Infectious Diseases and Oncology

Increasing diagnostic testing for infectious diseases and cancer is another important market driver. The growing number of molecular tests for viral and bacterial infections has increased demand for reliable nucleic acid extraction technologies.

In oncology, automated extraction is becoming increasingly important for applications such as early cancer detection, molecular profiling, minimal residual disease monitoring, and companion diagnostics. These applications often require high-quality DNA or RNA from complex clinical specimens.

Compared with manual extraction, automated systems offer greater consistency, throughput, and reproducibility. This makes them particularly attractive to hospitals, clinical laboratories, and centralized reference laboratories facing rising sample volumes and pressure to deliver faster turnaround times.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86934

Reagents and Consumables Remain a Key Revenue Segment

The reagent and consumables segment accounted for 69.4% of the market in 2025, making it a major contributor to industry revenue. Extraction kits, cartridges, buffers, and magnetic beads are routinely required for laboratory testing, creating recurring demand.

Many automated extraction instruments are designed to operate with validated reagent systems. This helps laboratories maintain consistent extraction performance while creating a recurring purchasing model for manufacturers and suppliers.

North America Leads the Market

North America held the largest regional share at 41.6% in 2025. The region benefits from advanced healthcare infrastructure, widespread adoption of molecular diagnostics, strong biotechnology activity, and substantial investment in research and development.

The growing demand for precision medicine, genetic testing, and laboratory automation is expected to support continued adoption of automated nucleic acid extraction systems. Favorable reimbursement structures and stringent quality requirements also encourage laboratories to implement standardized and reproducible workflows.

Meanwhile, emerging markets across Asia-Pacific, Latin America, the Middle East, and Africa present significant opportunities. Investments in diagnostic infrastructure, healthcare modernization, cancer screening, and molecular testing are creating new demand for automated laboratory technologies.

Competitive Landscape and Future Outlook

Major companies operating in the automated nucleic acid extraction market include Thermo Fisher Scientific, QIAGEN, Revvity, MP Biomedicals, F. Hoffmann-La Roche, Agilent Technologies, Promega, Bio-Rad Laboratories, Takara Bio, Analytik Jena, 3CR Bioscience, HiMedia Laboratories, Biogenuix, and GeneAll Biotechnology.

Going forward, opportunities will center on cost-effective systems, reagent-flexible platforms, integrated sample-to-result workflows, and solutions designed for emerging markets. As molecular testing volumes continue to rise and laboratories increasingly prioritize automation, standardization, and efficiency, the automated nucleic acid extraction market is expected to maintain strong growth through 2036.

Media Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453